Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1411-1422

  Poirier, Agnès ^a   Cascais, Anne Christine ^a   Bader, Urs ^a   Portmann, Renée ^a   Brun, Marie Elise ^a   Walter, Isabelle ^a   Hillebrecht, Alexander ^a   Ullah, Mohammed ^a   Funk, Christoph ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DRUG; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOASSAY; CALIBRATION; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; DRUG INTERACTION; HUMAN; IN VITRO STUDY; METABOLISM; PERMEABILITY; PHYSIOLOGY; PROCEDURES; SWINE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL TRANSPORT; CALIBRATION; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM; DIGOXIN; DRUG INTERACTIONS; HUMANS; IN VITRO TECHNIQUES; P-GLYCOPROTEIN; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SWINE;

EID: 84906861000     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057943     Document Type: Article

References (47)

1. Agarwal S, Arya V, and Zhang L (2013) Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1) ]/IC(50) and [I(2) ]/IC(50) criteria in the P-gp decision tree. J Clin Pharmacol 53:228-233.
2. 50) using various in vitro experimental systems: implications for universal digoxin DDI risk assessment decision criteria. Drug Metab Dispos 41:1347-1366.
3. Berginc K, Žakelj S, and Kristl A (2010) In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 49:373-384.
4. Caruso A, Alvarez-Sánchez R, Hillebrecht A, Poirier A, Schuler F, Lavé T, Funk C, and Belli S (2013) PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation. Biochem Pharmacol 85:1684-1699.
5. Chen C, Hanson E, Watson JW, and Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318. (Pubitemid 36249686)
6. Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, and Lee CA (2010) Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398-411.
7. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang SM, and Lesko LJ (1999) FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 39:899-910. (Pubitemid 30644025)
8. Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, and Palm J, et al. (2013) Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions. Drug Metab Dispos 41:1367-1374.
9. Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, and Surry DD (2011) The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos 39:275-282.
10. Fawcett T (2004) ROC graphs: notes and practical considerations for data mining researchers. Technical Report HPL-2003-4. Hewlett-Packard Labs, Palo Alto, CA.
11. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
12. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
13. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
14. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, and Sandmann S (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372-380.
15. Gramatté T and Oertel R (1999) Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239-245. (Pubitemid 29451755)
16. Gramatté T, Oertel R, Terhaag B, and Kirch W (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59:541-549. (Pubitemid 26191376)
17. Hassan HE, Myers AL, Lee IJ, Coop A, and Eddington ND (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 96:2494-2506. (Pubitemid 47477902)
18. Hellinger E, Veszelka S, Tóth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Háda V, Nakagawa S, and Duy TD, et al. (2012) Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 82:340-351.
19. Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, and Schaefer O (2014) Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers. Drug Metab Dispos 42:250-256.
20. Johnson BF, Smith G, and French J (1977) The comparability of dosage regimens of Lanoxin tablets and Lanoxicaps. Br J Clin Pharmacol 4:209-211. (Pubitemid 8068440)
21. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
22. Kanaan M, Daali Y, Dayer P, and Desmeules J (2009) Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol 105:199-206.
23. Kawashima M, Harada S, and Tango T (2002) Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol 41:701-706. (Pubitemid 35252053)
24. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, and Garner C (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125-131.
25. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037. (Pubitemid 35424386)
26. Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, Chu X, and Yabut J (2012) Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. J Pharmacol Toxicol Methods 65:64-74.
27. Moons T, de Roo M, Claes S, and Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193-1211.
28. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
29. RCoreTeam (2012) R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria.
30. Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, and Smith BJ (2013) In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos 41:1575-1583.
31. Richards DB, Spence R, Mandagere A, Henderson LS, and Magee MH (2011) Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers. J Clin Pharmacol 51:102-106.
32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, and Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77-84.
33. Schwab D, Fischer H, Tabatabaei A, Poli S, and Huwyler J (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716-1725. (Pubitemid 36444224)
34. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
35. Singh SK, Shawer M, Andrus PK, Raub TJ, and Vrbanac JJ (2003) Ocular delivery screening scheme for systemically administered ophthalmic drugs (Abstract). Invest Ophthalmol Vis Sci 44:4426.
36. Spahn-Langguth H and Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367. (Pubitemid 32166734)
37. Sugimoto H, Hirabayashi H, Amano N, and Moriwaki T (2013) Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Drug Metab Dispos 41:683-688.
38. Sugimoto H, Hirabayashi H, Kimura Y, Furuta A, Amano N, and Moriwaki T (2011a) Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across bloodbrain barrier in rats. Drug Metab Dispos 39:8-14.
39. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, and Moriwaki T (2011b) Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100:4013-4023.
40. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213. (Pubitemid 46956363)
41. Tachibana T, Kato M, Watanabe T, Mitsui T, and Sugiyama Y (2009) Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430-443.
42. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
43. Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, and Feng B; International Transporter Consortium (2013) Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther 94:113-125.
44. Wandel C, Kim R, Wood M, and Wood A (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920. (Pubitemid 34266685)
45. Wittgen HG, Greupink R, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, and Russel FG (2012) Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. Mol Pharm 9:1351-1360.
46. Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.
47. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168. (Pubitemid 32324448)